Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
Data to be presented at the 2021 ISIRV-WHO Virtual Conference WALTHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new in vitro data demonstrating retained neutralizing activity of its monoclonal antibody […]